Eric Tichy

Jamestown

Fire scanner enthusiast. Alden, NY native. Go Bills

Articles

Cost Savings Potential Associated With the Use of Biosimilars

1 week ago | ajmc.com | Ryan Haumschild |Eric Tichy

Author(s):,Panelists discuss how biosimilars for adalimumab have faced unique challenges in the prescription benefit space compared with earlier oncology biosimilars, highlighting the importance of interchangeability designation, advance planning, and stakeholder education when implementing biosimilar adoption strategies.
Perspectives and Future Directions in Biosimilar Health Care Delivery

Mar 7, 2025 | managedhealthcareexecutive.com | Eric Tichy

March 7, 2025By A panelist discusses how managing biosimilars requires close collaboration between payers and health systems to optimize patient care and cost savings, while sharing insights about program implementation challenges across different care settings and emphasizing the importance of robust operational frameworks. Video content above is prompted by the following: What would you like your payer colleagues to know about the use of biosimilars in the health system?
Looking Ahead: Strategic Planning for Biosimilar Integration

Feb 28, 2025 | managedhealthcareexecutive.com | Eric Tichy

February 28, 2025By A panelist discusses how their institution is proactively adapting their formulary review processes and infrastructure to handle the growing biosimilar pipeline, while anticipating increased competition will drive strategic shifts in contracting and necessitate more flexible approaches to formulary management in the coming years. Video content above is prompted by the following: How are you preparing for the increasing number of biosimilars entering the market?
Stakeholder Management and Interoperability of Biosimilars

Feb 21, 2025 | managedhealthcareexecutive.com | Eric Tichy

February 21, 2025By A panelist discusses how their institution implements robust safety protocols including distinct labeling, electronic health record alerts, and staff education to prevent dispensing errors when managing multiple biosimilars, while also conducting targeted educational outreach to address stakeholder concerns about interchangeability.
The Unique Challenges, Growth in the Business of Health-System Pharmacy

Feb 20, 2025 | drugtopics.com | Brian Nowosielski |Eric Tichy

Health-system pharmacy has seen impactful growth in the recent past. However, as market pressures and regulatory framework create barriers in a unique health care landscape, the business of keeping health systems sustainable has become a unique challenge for pharmacists and other health-system providers. “Health-system pharmacy has grown alongside the rapid growth of specialty pharmacy.
Financial and Operational Considerations of Implementing Biosimilars

Feb 14, 2025 | managedhealthcareexecutive.com | Eric Tichy

February 14, 2025By A panelist discusses how payer contract requirements and reimbursement policies significantly influence their institution’s biosimilar adoption strategy, requiring careful analysis of net cost benefits when weighing potential savings against the operational complexities of managing multiple products. Video content above is prompted by the following: How do payer contracts and reimbursement policies influence your biosimilar adoption decisions?
Decision-Making and Evidence Evaluation of Biosimilars

Feb 7, 2025 | managedhealthcareexecutive.com | Eric Tichy

February 7, 2025By A panelist discusses how their institution prioritizes cost savings and reliable supply chain considerations when selecting biosimilars for formulary inclusion, while also weighing switching study evidence, addressing stakeholder concerns through education, and implementing protocols to overcome barriers such as electronic health record integration and prior authorization challenges.
Q&A: Regulatory, Administrative Framework Creates Barriers for Health-System Pharmacy

Feb 4, 2025 | drugtopics.com | Brian Nowosielski |Eric Tichy

Due to bagging tactics, cost shifting between payers and beneficiaries, and regulatory framework that blurs the lines of which providers can administer what, the business of health care in the US has grown increasingly challenging for health-system pharmacy.
One Institution’s Evidence-Based Approach to Adopting Biosimilars

Feb 1, 2025 | managedhealthcareexecutive.com | Eric Tichy

February 1, 2025By A panelist discusses how their institution evaluates biosimilars for formulary inclusion through a systematic review process that examines clinical data, safety profiles, and cost implications while prioritizing operational efficiency, patient access, and seamless transitions between reference products and biosimilars.
Q&A: How Health Systems Must Navigate Pharmacy, Medical Benefits

Jan 27, 2025 | drugtopics.com | Brian Nowosielski |Eric Tichy

With health systems uniquely positioned to witness the growth of both pharmacy and primary care, the pharmacists within health-systems pharmacies are too expected to understand the nuances of prescription drug and medical benefits amongst their setting. “Health-system pharmacy has grown alongside the rapid growth of specialty pharmacy,” said Eric Tichy, PharmD, MBA, Mayo Clinic Division Chair and Associate Professor at the Mayo Clinic College of Medicine and Science.